Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
Cancers, 2022 Liquid biopsy has improved significantly over the last decade and is attracting attention as a tool that can complement tissue biopsy to evaluate the genetic landscape of solid tumors. In the present study, we evaluated the usefulness of liquid biopsy in daily oncology practice in different clinical contexts.
Josep Gumà +18 more
openaire +2 more sources
Translational Application of Circulating DNA in Oncology: Review of the Last Decades Achievements
Cells, 2019 In recent years, the introduction of new molecular techniques in experimental and clinical settings has allowed researchers and clinicians to propose circulating-tumor DNA (ctDNA) analysis and liquid biopsy as novel promising strategies for the early ...
Natalia O. Tuaeva +12 more
doaj +1 more source
Liquid biopsy genotyping in lung cancer: ready for clinical utility? [PDF]
, 2017 Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the circulation. Despite complicated collection methods and the requirement for technique-dependent platforms, it has generated substantial interest due, in part, to its ...
Chen, Yi-Lin +7 more
core +1 more source
Indonesian Journal of Cancer, 2023 Background:The prognosis for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) is greatly improved when treated with tyrosine kinase inhibitor (TKI).
Haryati Haryati +2 more
doaj +1 more source
ctDNA Reveals Targetable Alterations [PDF]
Cancer Discovery, 2020 Abstract In the plasmaMATCH trial, researchers performed circulating tumor DNA testing on patients with advanced breast cancer and matched those with ESR1, HER2, or AKT1 alterations to targeted therapies. Patients with HER2 and AKT1 mutations experienced response rates greater than 22% with durable benefit.
openaire +1 more source
EGFR inhibitor as second-line therapy in a patient with mutant RAS metastatic colorectal cancer: circulating tumor DNA to personalize treatment [PDF]
, 2018 A 47-year-old male patient presented in March 2016 to our unit with a palpable painless left supraclavicular mass. A whole-body contrastenhanced computed tomography (CT) scan revealed a left supraclavicular lymphadenopathy, transverse colon thickening ...
Cortesi, Enrico +3 more
core +1 more source
Review of precision cancer medicine: Evolution of the treatment paradigm. [PDF]
, 2020 In recent years, biotechnological breakthroughs have led to identification of complex and unique biologic features associated with carcinogenesis. Tumor and cell-free DNA profiling, immune markers, and proteomic and RNA analyses are used to identify ...
Fountzilas, Elena +3 more
core +1 more source
Transient disappearance of RAS mutant clones in plasma: A counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer [PDF]
, 2019 Genomic studies performed through liquid biopsies widely elucidated the evolutionary trajectory of RAS mutant clones under the selective pressure of EGFR inhibitors in patients with wild type RAS primary colorectal tumors. Similarly, the disappearance of
Belardinilli, Francesca +9 more
core +1 more source
eLife, 2021 We developed genetic-epigenetic tissue mapping (GETMap) to determine the tissue composition of plasma DNA carrying genetic variants not present in the constitutional genome through comparing their methylation profiles with relevant tissues.
Wanxia Gai +18 more
doaj +1 more source
Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives [PDF]
, 2019 Oral cancer is the sixth most common cancer type in the world, and 90% of it is represented by oral squamous cell carcinoma (OSCC). Despite progress in preventive and therapeutic strategies, delay in OSCC diagnosis remains one of the major causes of high
Campisi, Giuseppina +5 more
core +1 more source